Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer: An Open-label Randomized Controlled Phase II Study (The TOTAL Trial)

NCT06940388 is registered in ClinicalTrials.gov with brenner baruch as lead sponsor.

NCT NCT06940388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06940388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer: An Open-label Randomized Controlled Phase II Study (The TOTAL Trial)
Lead sponsor
brenner baruch
Phase
Phase 2
Overall status
Recruiting
Start date
July 23, 2025
Completion date
August 31, 2030
Enrollment
134 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer (larc)